News >

Trastuzumab Deruxtecan Improves Survival in Heavily Pretreated HER2+ Gastric/GEJ Cancer

Jason M. Broderick @jasoncology
Published: Monday, Jan 27, 2020

Jose Baselga, MD, PhD, executive vice president, Oncology R&D, AstraZenec

José Baselga, MD, PhD

Trastuzumab deruxtecan (Enhertu) improved overall survival (OS) versus chemotherapy in patients with heavily pretreated unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) cancer, according to topline findings from the phase II DESTINY-Gastric01 trial.1



  1. Phase II DESTINY-Gastric01 trial of Enhertu versus chemotherapy met primary endpoint [news release]. AstraZeneca; January 27, 2020. Accessed January 27, 2020.
  2. Shitara K, Iwata H, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol. 2019;20(6):827-836. doi: 10.1016/S1470-2045(19)30088-9.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication